Preconception SGLT2 or DPP4 inhibitor use and adverse pregnancy outcomes
Authors' conclusion
Neither SGLT2i nor DPP4i use before pregnancy was associated with a difference in A1c, or a higher risk of selective adverse outcomes, compared to sulfonylureas. Future larger studies are required, including assessment of medication use after conception, during the critical period of embryogenesis.
Study context
- Population
- Women eligible for free medication coverage with a recognized pregnancy, Ontario, Canada, April 2007–November 2021
- Exposure
- Preconception SGLT2i or DPP4i vs SU
- Outcome
- Periconceptional A1c
- Follow-up
- Periconception
Methodological detailspropensity score overlap weighting
- Propensity score overlap weighting
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | RR (95 % CI) | |
|---|---|---|
| Pregnancy loss (miscarriage, induced abortion or stillbirth)SGLT2ivs SulfonylureaExclusively prescribed SGLT2i; lowest risk · propensity score overlap weighting | 0.51 (0.22–0.91) | |
| 0.20.5125Relative risk (log scale) |
Any congenital anomaly at birth
- Did not differ significantly comparing DPP4i or SGLT2i to SU
- Propensity score overlap weighting
Original publication
Preconception SGLT2 or DPP4 inhibitor use and adverse pregnancy outcomes. Diabetes Res Clin Pract. Published 7 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →